Skip to main content

Posts

Showing posts with the label arbovirus

Serologic #Surveillance for #Orthoflaviviruses and #Chikungunya Virus in #Bats and #Opossums in #Chiapas, #Mexico

Abstract We performed serologic surveillance for selected arthropod-borne viruses (arboviruses) in bats and opossums in the Lacandona Rainforest, Chiapas, Mexico , in 2023–2024. Sera were collected from 94 bats of at least 15 species and 43 opossums of three species. The sera were assayed by the plaque reduction neutralization test (PRNT) for antibodies to eight orthoflaviviruses ( dengue viruses 1–4, St. Louis encephalitis virus , T’Ho virus, West Nile virus, and Zika virus ) and one alphavirus (chikungunya virus; CHIKV). Twelve (12.8%) bats and 15 (34.9%) opossums contained orthoflavivirus-specific antibodies . One bat (a Jamaican fruit bat) was seropositive for Zika virus , and 11 bats contained antibodies to an undetermined orthoflavivirus , as did the 15 opossums. All bats and most opossums seropositive for an undetermined orthoflavivirus had low PRNT titers, possibly because they had been infected with another (perhaps unrecognized) orthoflavivirus not included in the PRNTs. Anti...

#Chikungunya virus virus-like particle #vaccine #safety and immunogenicity in adults older than 65 years: a phase 3, randomised, double-blind, placebo-controlled trial

Summary Background Adults older than 65 years are at increased risk for atypical presentations of chikungunya disease, as well as for severe outcomes including death. Methods In this phase 3, randomised, double-blind, placebo-controlled, parallel-group trial, adults aged 65 years and older received a single intramuscular dose of Vimkunya (previously chikungunya virus virus-like particle vaccine) or placebo at ten sites in the USA. Participants, clinical site personnel, and the sponsor were masked to individual treatment assignments until all participants had completed their involvement in the trial and the database was cleaned and locked. Baseline and postvaccination chikungunya virus serum neutralising antibody (SNA) titres (NT80) were assessed at selected timepoints. Safety was assessed up to 183 days after dose administration in all participants from the exposed population who provided safety assessment data. This trial is registered with ClinicalTrials.gov, NCT05349617, and is comp...

The spatiotemporal #ecology of #Oropouche virus across Latin #America: a multidisciplinary, laboratory-based, modelling study

Summary Background Latin America has been experiencing an Oropouche virus (OROV) outbreak of unprecedented magnitude and spread since 2023–24 for unknown reasons. We aimed to identify risk predictors of and areas at risk for OROV transmission. Methods In this multidisciplinary, laboratory-based, modelling study, we retrospectively tested anonymised serum samples collected between 2001 and 2022 for studies on virus epidemiology and medical diagnostics in Bolivia, Brazil, Colombia, Costa Rica, Ecuador, and Peru with nucleoprotein-based commercial ELISAs for OROV-specific IgG and IgM antibodies. Serum samples positive for IgG from different ecological regions and sampling years were tested against Guaroa virus and two OROV glycoprotein reassortants (Iquitos virus and Madre de Dios virus) via plaque reduction neutralisation testing (PRNT) to validate IgG ELISA specificity and support antigenic cartography. Three OROV strains were included in the neutralisation testing, a Cuban OROV isolate...

#Clinical presentation of #Oropouche virus #infection: A systematic review and meta-analysis

Abstract Background The recent surge in incidence and geographic spread of OROV infections poses an escalating threat to global public health. However, studies exploring the clinical signs of OROV infection remains exceedingly limited. Methods We searched for OROV studies published until June 17, 2024, in several electronic databases including MEDLINE, EMBASE, SCOPUS, and the Cochrane Library. Results In total, 15 studies involving 806 patients with OROV infection were eligible for inclusion. General symptoms with fever and headache were the most common. Gastrointestinal disturbances like nausea/vomiting, anorexia , and odynophagia were also prevalent, along with ocular symptoms , mainly retro-orbital pain, photophobia, and redness . Respiratory symptoms , such as cough, sore throat and nasal congestion, are present, and skin-related issues like rash, pruritus, and pallor were also identified. Conclusion Overall, this study provides a foundational understanding of OROV’s clinical manif...

#Congenital #Oropouche in #Humans: Clinical Characterization of a Possible New #Teratogenic Syndrome

Abstract Oropouche fever is caused by the Oropouche virus (OROV; Bunyaviridae , Orthobunyavirus), one of the most frequent arboviruses that infect humans in the Brazilian Amazon . This year, an OROV outbreak was identified in Brazil , and its vertical transmission was reported, which was associated with fetal death and microcephaly. We describe the clinical manifestations identified in three cases of congenital OROV infection with confirmed serology (OROV-IgM) in the mother-newborn binomial . One of the newborns died , and post-mortem molecular analysis using real-time RT-qPCR identified the OROV genome in several tissues . All three newborns were born in the Amazon region in Brazil , and the mothers reported fever, rash, headache, myalgia, and/or retro-orbital pain during pregnancy . The newborns presented with severe microcephaly secondary to brain damage and arthrogryposis , suggestive of an embryo/fetal disruptive process at birth . Brain and spinal images identified overlapping su...

Co-Circulation of 2 #Oropouche Virus #Lineages during #Outbreak, #Amazon Region of #Peru, 2023–2024

Abstract We describe introduction of the 2022–2023 Oropouche virus lineage from Brazil , which has caused large-scale outbreaks throughout Brazil , into the Amazon Region of Peru . This lineage is co-circulating with another lineage that was circulating previously. Our findings highlight the need for continued surveillance to monitor Oropouche virus in Peru. Source: US Centers for Disease Control and Prevention,  https://wwwnc.cdc.gov/eid/article/31/4/24-1748_article ____

Prevalence, clinical #management, and #outcomes of #adults hospitalised with endemic #arbovirus illness in southeast #Europe (MERMAIDS-ARBO): a prospective observational study

Summary Background Arboviruses have expanded into new regions in Europe , yet data indicate gaps in disease notifications and a risk of further spread. We aimed to report on prevalence, clinical management, and outcomes of endemic arbovirus infections in southeast Europe. Methods In this prospective observational study (MERMAIDS-ARBO), we enrolled adults (age ≥18 years) hospitalised with an arbovirus-compatible disease syndrome within 21 days of symptom onset across 21 hospitals in seven countries in southeast Europe over four arbovirus seasons (May 1–Oct 31, during 2016–19). We obtained data from case report forms completed by site investigators on admission and discharge. Participants were excluded if they had non-infectious CNS disorders, symptoms of another confirmed cause, an identified focal source of infection, or symptoms caused by recurrence of a pre-existing condition. The primary outcome was the proportion of participants with confirmed or probable acute infections with West...

#Zika virus disease - #India

Situation at a glance Between 1 January and 31 December 2024, a cumulative total of 151 Zika virus disease (ZVD) cases were reported from three states in India ( Gujarat, Karnataka, and Maharashtra states). Maharashtra State reported a cumulative total of 140 ZVD cases through the Integrated Disease Surveillance Programme (IDSP). Additionally, Karnataka and Gujarat states reported ten and one cases , respectively, in 2024. As of 31 December 2024, no cases of microcephaly and/or Guillain-Barre syndrome (GBS) associated with this outbreak have been reported. Zika virus (ZIKV) is transmitted to humans by the bite of an infected Aedes mosquito . Zika virus is also transmitted from mother to fetus during pregnancy, as well as through sexual contact, transfusion of blood and blood products, and possibly through organ transplantation. There is no specific treatment available for Zika virus infection or disease. Description of the situation Between 1 January and 31 December 2024, a cumulative ...

#Bussuquara Virus: A Neglected #Orthoflavivirus with Broad Distribution Across Central and South #America and the #Caribbean

Abstract Bussuquara virus (BSQV) was first discovered in the Brazilian Amazon in 1956 . It is an arthropod-borne virus (arbovirus) in the genus Orthoflavivirus , family Flaviviridae . Since its discovery, BSQV has been sporadically detected across the South ( Brazil, Columbia, and Argentina ) and Central ( Panama and Mexico ) America and the Caribbean ( Grenada ), but there is minimal BSQV surveillance due to limited public health awareness and a lack of specific or sensitive diagnostics. BSQV exposure has been reported in a wide range of host and vector species , including humans . Little information is available in the literature and herein we summarize the published historical findings on BSQV and suggest a pathway for future studies to better understand its potential emergence into human populations. Source: Viruses,  https://www.mdpi.com/1999-4915/17/2/183 _____

Lack of Competence of #US #Mosquito Species for Circulating #Oropouche Virus

Abstract Given recent outbreaks of Oropouche virus in Latin America and >100 confirmed travel-associated cases in the United States , we evaluated the competence of US vectors , including Aedes albopictus, Culex quinquefasciatus, Culex pipiens , and Anopheles quadrimaculatus mosquitoes . Results with historic and recent isolates suggest transmission potential for those species is low . Source: Emerging Infectious Diseases Journal,  https://wwwnc.cdc.gov/eid/article/31/3/24-1886_article _____

Prior #influenza virus #infection alleviates an #arbovirus #encephalitis by reducing viral titer, #inflammation, and cellular infiltrates in the central nervous system

ABSTRACT Respiratory and encephalitic virus infections represent a significant risk to public health globally . Detailed investigations of immunological responses and disease outcomes during sequential virus infections are rare. Here, we define the impact of influenza virus infection on a subsequent virus encephalitis . We used a model system in which mice were given influenza A virus (IAV) infection 8 days prior to Semliki Forest virus (SFV) infection (IAV→SFV). IAV infection clearly attenuated the subsequent SFV infection with reduced titers of infectious SFV and lower levels of cytokines and chemokines in the central nervous system ( CNS ). In contrast, the SFV viremia in both IAV→SFV and SFV-only mice was comparable. Increased type I interferon (IFN) levels in the CNS after IAV infection might have contributed to some level of protection towards SFV infection in the CNS, suggesting that early control of SFV replication in the CNS during IAV→SFV infection led to reduced adaptive res...

#Persistence of #Oropouche virus in #body #fluids among imported cases in #France, 2024

{Extract} Since late 2023, more than 10 000 locally acquired cases of Oropouche virus have been reported in the Americas .1 Here, we describe the first cluster of Oropouche virus imported into France from Cuba , where transmission has been ongoing since at least May, 2024.2 Oropouche virus infection was documented in a group of five women (patients 1–5, confirmed cases) travelling to Cuba with two infants (patients 6–7, suspect cases) between July 28 and Aug 14, 2024. During their stay, patients 1–5 developed a dengue-like syndrome lasting 2–11 days, presenting symptoms similar to those described in the literature for Oropouche virus infection (appendix p 8).3 After recovery, patients 1, 2, and 5 experienced symptom relapse upon their return to France; the observed relapse rate aligns with recent estimates suggesting that 60% of patients with Oropouche virus experience a biphasic illness (appendix pp 7–8).4 During relapse, patient 1 sought medical advice, becoming the first diagnosed O...